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Phenolphthalein, the active ingredient in
many laxatives, was recently found to be a
multisite/multispecies carcinogen in ani-
mals (1). In some of the animal experi-
ments, the dose of phenolphthalein (per
unit body surface area) found to be carcino-
genic was within an order of magnitude of
that prescribed for humans. Although col-
orectal neoplasia in animals was not
observed, a link between laxative use and
colorectal cancer in humans has been
reported (2). Because of the finding that
phenolphthalein is a carcinogen and
because of the association of laxative use
with risk of colorectal cancer, we hypothe-
sized that use of phenolphthalein-contain-
ing laxatives increases risk of adenomatous
colorectal polyps. Colorectal adenomas are
precursors of colorectal cancer (3,4), and
adenomas and cancer of the large bowel
have many risk factors in common (5,6). In
three recent case-control studies ofrisk fac-
tors for adenomatous colorectal polyps, lax-
ative use was ascertained, thus providing a
means bywhich to test the hypothesis.
Methods
The data considered in this report come from
a case-control study conducted in Los
Angeles, California, in 1991-1993 and two
studies conducted in North Carolina in
1988-1990 and 1992-1995. Details ofeach
study are presented elsewhere (7-1(). In all
three studies, subjects were selected from
among those undergoing an endoscopic pro-
cedure at designated medical facilities (Table
1). All cases had histologically confirmed
adenomatous polyps. Controls in Los
Angeles had no polyps of any type and in
North Carolina, controls had no adenoma-
tous polyps. Controls in Los Angeles were
individually matched to cases by age, sex,
medical facility, and period of exam; con-
trols in North Carolinawere not matched to
cases. In all three studies, subjects were
excluded if they had previous bowel cancer
or adenoma, bowel surgery, inflammatory
bowel disease, polyposis, or could not speak
English. Subjects with colitis due to radia-
tion or infection were excluded in North
Carolina. In Los Angeles and in the second
North Carolina study (North Carolina-2),
subjects were free ofinvasive cancer, whereas
in the first North Carolina study (North
Carolina-1), 27 subjects with colorectal can-
cer were included in the case group. Other
differences were that in Los Angeles subjects
had to be residents ofLosAngeles or Orange
County, and in North Carolina subjects had
to have a satisfactory bowel preparation and
a complete endoscopy. The lower response
rate in the second North Carolina study as
compared with the first was because the pro-
tocol included a rectal biopsy and blood
draw. Informed consent was obtained from
all participants.
In all three studies, subjects provided
information about themselves after the
endoscopy. Dietary data were collected in
Los Angeles using a self-administered food-
frequency questionnaire (11); dietary data
were collected in North Carolina over the
phone using a similar instrument (12).
Data on laxative use and other nondietary
variables were collected by personal inter-
view in Los Angeles and over the telephone
in North Carolina. In Los Angeles, subjects
were asked, "In the year before your sig-
moidoscopy, did you take any of the fol-
lowing substances at least once a week, to
maintain regular bowel movements?" The
list of laxatives read to the subjects con-
tained no phenolphthalein-containing laxa-
tives, but included the category other laxa-
tive preparations. Ifthe subject reported use
of a laxative in this category, the prepara-
tion was recorded. For each agent reported,
the number ofdays per week used and the
total number of years of use was ascer-
tained. In North Carolina, subjects were
asked "How often do you take laxatives?"
and "Which laxative do you take most
often?" In all studies, the responses to ques-
tions about the preparation used were
reviewed without knowledge of subjects'
case-control status, and laxatives were clas-
sified as containing phenolphthalein if one
of the following brands was reported:
Agoral, Alophen, Colax, Correctol, Dialose,
Doxidan, Espotabs, Evac-U-Gen, Evac-U-
Lax, Ex-Lax, Feen-A-Mint, FemiLax,
Kondremul, LaxCaps, Lax-Pills, Medilax,
Modane, Phenolax, or Prulet (13). In the
Los Angeles study, questions about consti-
pation were not asked; however, frequency
ofbowel movements in the year before sig-
moidoscopy was ascertained. In the North
Carolina studies, subjects were asked: "Are
you ever constipated?" as well as a question
about frequency ofbowel movements.
Results from logistic regression models
adjusted for selected a priori potentially
confounding factors are presented (see
Table 3 for list of covariates). For the Los
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Angeles data, adjustment for smoking
accounted for most of the difference
between the crude and adjusted odds ratios
(2.3 vs. 1.8); in the second North Carolina
study, age accounted for most ofthe differ-
ence (1.6 vs. 1.1). Additional adjustment
for race, body mass index, or use of non-
steroidal anti-inflammatory agents (the lat-
ter was available for Los Angeles and the
second North Carolina study) had no
important effect on the results. The pair
matching in Los Angeles was retained in
the analysis by use of conditional models.
We chose not to pool the results because
we thought colonoscopy- and flexible sig-
moidoscopy-based study results would not
be strictly comparable, due to the possibili-
ty that controls in the sigmoidoscopy-based
study might have right-sided polyps.
Further, the differences between the North
Carolina studies described above supported
the separate presentation ofresults.
Results
With subjects from each study categorized
according to whether phenolphthalein-con-
taining laxatives were used at least once a
week (Table 2), the overall prevalence of
use was 1.3% in Los Angeles, 4.2% in
North Carolina-1, and 2.3% in North
Carolina-2. Consequently, cell counts were
small and confidence intervals were wide
(Table 2). Nonetheless, a consistent associ-
ation of phenolphthalein-containing laxa-
tive use with riskofpolyps was not present.
Use of other laxatives was not associated
with risk. Adjustment ofresults for dietary
factors had little effect on results; thus,
only the fully adjusted odds ratios are
shown.
More detailed analyses revealed little
else ofimportance. In the LosAngeles data,
we examined frequency ofuse; the adjusted
odds ratio was 1.2 (CI, 0.7-2.1) for each
day per week a phenolphthalein-containing
laxative was used. The adjusted odds ratio
per 10 years ofuse ofphenolphthalein-con-
taining laxative was 0.7 (CI, 0.1-3.6), and
the adjusted odds ratio per 50 times a phe-
nolphthalein-containing laxative was taken
was 1.0 (CI, 0.9-1.1). In neither North
Carolina study was frequency ofuse related
to risk. The adjusted odds ratio for each
day per week a phenolphthalein-containing
laxative was used was 1.0 (CI, 0.9-1.1) in
both studies. The North Carolina-2 data
were too sparse to allow an assessment of
site-specific effects for phenolphthalein-
containing laxatives. The North Carolina-1
data suggested no predilection for an asso-
ciation on either side ofthe large bowel.
In Los Angeles, the adjusted odds ratio
for having a bowel movement more than 7
times/week, as compared to less than 7
Table 1. Characteristics ofthe three studies
Study
Attribute Los Angeles North Carolina-1 North Carolina-2
Dates subjects enrolled 1991-1993 1988-1990 1992-1995
Endoscopy
Type Sigmoidoscopy Colonoscopy Colonoscopy
Indication (%)a Screening (45) Bleeding (57) Bleeding (35)
Minor symptoms (15) Anemia (10) Anemia (8)
Notstated (41) Other (33) Other(57)b
Cases (n) 488 236 142
Controls (n) 488 409 169
Age range (years) 50-74 30-89 30-88
Mean age (years) 62 60 59
Sex (% female) 34 58 53
Response rate (%) 83 83 45
aTotals do notequal 100% for Los Angeles due to rounding.
bAmongthe otherindications, the mostfrequentwasfollow-upfora previous nonadenomatous polyp (17.4%).
Table2. Number ofsubjects in three studies, according to use and type of laxative
Study
Use of laxative Los Angeles North Carolina-i a North Carolina-2b
(.once perweek) Cases Controls Cases Controls Cases Controls
No 401 412 206 350 123 145
Yes
Phenolphthalein-containing 9 4 9 18 4 3
Othertype 78 72 21 41 15 21
alnthe North Carolina-1 study(1988-1990), phenolphthalein-containing laxatives were used occasionally by82
subjects, once permonth by28subjects, once a week by21 subjects, and once a day ormore by6 subjects.
binthe North Carolina-2 study(1992-1995), phenolphthalein-containing laxatives were used occasionally by27
subjects, once permonth by 13subjects, once a week by6subjects, and once a day or more by 1 subject
Table 3. Multivariate-adjusted odds ratios (95% confidence intervals) for adenomatous colorectal polyps
associated with laxative use in three studies, according to use and type of laxative
Use of laxative Study
(.once perweek) Los Angelesa North Carolina-1b North Carolina-2c
No 1
Yes
Phenolphthalein-containing 1.8(0.5-6.2) 1.0(0.4-2.2) 1.1 (0.2-5.7)
Othertype 1.3(0.9-1.9) 1.0(0.5-1.7) 0.9(0.4-1.8)
aThe adjustmentfactors used were alcohol, smoking, vigorous activity, and intake of energy, saturated fat,
and fruits and vegetables.
bThe adjustmentfactors used were age, sex, alcohol, smoking, leisure activity, and intake of energy, total
fat, and fiberfrom fruits and vegetables for North Carolina-1 (1988-1990).
cThe adjustment factors used were age, sex, alcohol, smoking, hard physical activity, and intake of ener-
gy,total fat, and fiberfrom fruits and vegetables for North Carolina-2 (1992-1995).
times/week, was 1.2 (CI, 0.8-1.8). When
the results for laxatives shown in Table 3
were additionally adjusted for frequency of
bowel movement, the odds ratios were
unchanged. In North Carolina, constipation
was not related to risk of polyps in either
study. The odds ratio for adenomas among
subjects having a bowel movement more
than 7 times/week, as compared to less than
7 times/week, was 1.0 in North Carolina-I
and 1.2 (CI, 0.8-1.8) in North Carolina-2.
For the North Carolina phenolphthalein
results shown in Table 3, additional adjust-
ment for constipation or bowel movement
did notmaterially alter the findings.
Discussion
In the populations studied, few subjects
reported using phenolphthalein-containing
laxatives with any appreciable frequency;
thus, the estimates of association in the
data are imprecise. In the North Carolina
studies, an association ofphenolphthalein-
containing laxative use with risk ofcolorec-
tal adenomas was not found. In the Los
Angeles study, the odds ratio of 1.8 associ-
ated with use once a week or more was sug-
gestive of an association, but the confi-
dence interval was wide. Although the Los
Angeles data also showed an increase in risk
with number of times a phenolphthalein-
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containing laxative was used per week, an
association with years of use or number of
times taken was not observed. Overall,
these data suggest use of phenolphthalein-
containing laxatives does not increase risk
ofadenomatous colorectal polyps.
Mechanistic studies suggest that phe-
nolphthalein is clastogenic and estrogenic;
this had led to its testing by the National
Toxicology Program (13). Phenolphthalein-
induced tumors were observed in rats
(pheochromocytoma, renal adenoma and
carcinoma) and in mice (histiocytic sarcoma,
lymphoma, and ovarian stromal cell tumor).
The type ofcancer causedbyan agent in ani-
mal models, however, does not always pre-
dict the affected site in humans (14). The
effects caused by phenolphthalein in the
National Toxicology Program studies sug-
gested that the mechanism of action was by
both estrogenic and other pathways (1).
Recent epidemiologic evidence shows that
use ofhormone replacement therapy reduces
risk of colorectal neoplasms (15). Thus, the
possibility exists that an adverse effect ofphe-
nolphthalein on colorectal adenomas was
balanced byaprotective estrogenic action.
Kune (16) examined the association of
colorectal cancer with any use of phenol-
phthalein-containing laxatives and found
the odds ratio to be 1.35 (not significant).
In the same study, the odds ratio associated
with any use oflaxatives ofany type was 1.0.
In a meta-analysis of 14 case-control studies
ofcathartic use and risk ofcolorectal cancer,
the odds ratio associated with use ofcathar-
tics was 1.46 (CI, 1.33-1.61) (2). This sum-
mary was based on study-specific estimates
that were not adjusted for constipation, and
constipation was also associated with risk.
Jacobs and White (17) recendy reported an
association of laxative use and risk of col-
orectal cancer, with an odds ratio of2.8 (CI,
1.0-4.6) for 350 or more lifetime uses com-
pared with no regular use. This association,
however, disappeared when adjusted for fre-
quency of constipation. Thus, the evidence
that laxative use is an independent risk fac-
tor for colorectal cancer appears weak. The
present data further suggest no evidence of
an association ofrecent laxative use with risk
ofadenomatous polyps.
Because data implicating phenol-
phthalein as a carcinogen were not available
at the start of these studies, the questions
used to ascertain laxative use were not
focused on use ofphenolphthalein-contain-
ing laxatives, nor were they especially
detailed in the history of use obtained. Use
of phenolphthalein-containing laxatives was
undoubtedly underestimated, and past use
was not specifically addressed. Misclassifi-
cation ofexposure caused true associations, if
any, to be underestimated. The accuracy of
the exposure measure can be further ques-
tioned because the condition precipitating the
endosocopy, if there was one, might have
affected laxative use. Finally, the rateofpartic-
ipation was sufficiently low in the second
North Carolinastudyas to raisethepossibility
ofbias due to nonresponse; however, the deci-
sion to participate was made before the sub-
jects knew if they had adenomatous polyps,
and both North Carolina studies gave the
same result. Potential shortcomings notwith-
standing, other results from the three studies
have been consistent with the general litera-
tureonriskfactors forcolorectalpolyps (7,8).
In summary, data from three studies do
not support the hypothesis that laxatives in
general or phenolphthalein in particular are
associated with presumed colon cancer pre-
cursors. Because the risk factors for cancer
and adenomas do not always appear to be
the same (18) and because the studies ana-
lyzed here were not designed to test the lax-
ative hypothesis, a definitive statement on
the role ofphenolphthalein in the etiology
ofcolorectal neoplasia would be premature.
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